Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle R Lofwall

Showing results (11-20 of 126) with videos related to

Pageof 13
Sort By:
The American Journal on Addictions|February 19, 2010
Pharmacy willingness to partner with office-based opioid dependence treatment providers in conducting random buprenorphine pill countsMichelle R Lofwall, Martha J Wunsch, Sharon L Walsh
Drug and Alcohol Dependence|January 3, 2012
Effects of cold pressor pain on the abuse liability of intranasal oxycodone in male and female prescription opioid abusersMichelle R Lofwall, Paul A Nuzzo, Sharon L Walsh
Journal of Addiction Medicine|June 23, 2025
Description of Physician Champion Efforts to Expand Buprenorphine Treatment in Primary Care and Explore a Quality Implementation Measure of Success: Buprenorphine as a Percentage of All Opioids PrescribedThaddeus R Salmon, Anna-Maria South, Michelle R Lofwall
Experimental and Clinical Psychopharmacology|November 23, 2006
Cognitive and subjective acute dose effects of intramuscular ketamine in healthy adultsMichelle R Lofwall, Roland R Griffiths, Miriam Z Mintzer
Journal of Community Psychology|March 17, 2023
Facilitating factors and barriers for use of medications to treat opioid use disorder (MOUD) among justice-involved individuals in rural AppalachiaMichele Staton, Erika Pike, Martha Tillson, et al.
Substance Abuse|July 12, 2019
Adoption of the 275-patient buprenorphine treatment waiver for treating opioid use disorder: A state-level longitudinal analysisHannah K Knudsen, Lewei Allison Lin, Michelle R Lofwall
Journal of Addiction Medicine|September 26, 2018
Substance Use Disorder Assessment, Diagnosis, and Management for Patients Hospitalized With Severe Infections Due to Injection Drug UseCrystal Jicha, David Saxon, Michelle R Lofwall, et al.
Addiction Biology|August 19, 2014
Pharmacodynamic effects of oral oxymorphone: abuse liability, analgesic profile and direct physiologic effects in humansShanna Babalonis, Michelle R Lofwall, Paul A Nuzzo, et al.
Experimental and Clinical Psychopharmacology|January 29, 2014
Aripiprazole effects on self-administration and pharmacodynamics of intravenous cocaine and cigarette smoking in humansMichelle R Lofwall, Paul A Nuzzo, Charles Campbell, et al.
Journal of Analytical Toxicology|June 8, 2013
Determination of oxycodone, noroxycodone and oxymorphone by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry in human matrices: in vivo and in vitro applicationsWenfang B Fang, Michelle R Lofwall, Sharon L Walsh, et al.
Pageof 13

Showing results (11-20 of 126) with videos related to

Sort By:
Pageof 13
The American Journal on Addictions|February 19, 2010
Pharmacy willingness to partner with office-based opioid dependence treatment providers in conducting random buprenorphine pill countsMichelle R Lofwall, Martha J Wunsch, Sharon L Walsh
Drug and Alcohol Dependence|January 3, 2012
Effects of cold pressor pain on the abuse liability of intranasal oxycodone in male and female prescription opioid abusersMichelle R Lofwall, Paul A Nuzzo, Sharon L Walsh
Journal of Addiction Medicine|June 23, 2025
Description of Physician Champion Efforts to Expand Buprenorphine Treatment in Primary Care and Explore a Quality Implementation Measure of Success: Buprenorphine as a Percentage of All Opioids PrescribedThaddeus R Salmon, Anna-Maria South, Michelle R Lofwall
Experimental and Clinical Psychopharmacology|November 23, 2006
Cognitive and subjective acute dose effects of intramuscular ketamine in healthy adultsMichelle R Lofwall, Roland R Griffiths, Miriam Z Mintzer
Journal of Community Psychology|March 17, 2023
Facilitating factors and barriers for use of medications to treat opioid use disorder (MOUD) among justice-involved individuals in rural AppalachiaMichele Staton, Erika Pike, Martha Tillson, et al.
Substance Abuse|July 12, 2019
Adoption of the 275-patient buprenorphine treatment waiver for treating opioid use disorder: A state-level longitudinal analysisHannah K Knudsen, Lewei Allison Lin, Michelle R Lofwall
Journal of Addiction Medicine|September 26, 2018
Substance Use Disorder Assessment, Diagnosis, and Management for Patients Hospitalized With Severe Infections Due to Injection Drug UseCrystal Jicha, David Saxon, Michelle R Lofwall, et al.
Addiction Biology|August 19, 2014
Pharmacodynamic effects of oral oxymorphone: abuse liability, analgesic profile and direct physiologic effects in humansShanna Babalonis, Michelle R Lofwall, Paul A Nuzzo, et al.
Experimental and Clinical Psychopharmacology|January 29, 2014
Aripiprazole effects on self-administration and pharmacodynamics of intravenous cocaine and cigarette smoking in humansMichelle R Lofwall, Paul A Nuzzo, Charles Campbell, et al.
Journal of Analytical Toxicology|June 8, 2013
Determination of oxycodone, noroxycodone and oxymorphone by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry in human matrices: in vivo and in vitro applicationsWenfang B Fang, Michelle R Lofwall, Sharon L Walsh, et al.
Pageof 13